story of the week
Carboplatin and/or Bevacizumab Plus Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
J. Clin. Oncol 2014 Aug 04;[EPub Ahead of Print], WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, CS Kuzma, TJ Pluard, G Somlo, ER Port, M Golshan, JR Bellon, D Collyar, OM Hahn, LA Carey, CA Hudis, EP WinerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.